Please login to the form below

Not currently logged in
Email:
Password:

VentiRx appoints James Kyle Bryan as chief medical officer

He has more than 20 years of experience in oncology

US-based biopharma VentiRx Pharmaceuticals has appointed Dr James Kyle Bryan as chief medical officer.

Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.

During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology.

This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian cancer and head and neck cancer.

“His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward,” said Dr Robert Hershberg, CEO of VentiRx. “We are delighted to have him join the VentiRx team.”

30th April 2013

From: Research

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...